Hexachlorophene is an agonist of the KCNQ1/KCNE1 potassium ion channel with an EC50 value of 4.61 μM. Hexachlorophene is also an inhibitor of the Wnt/β-catenin signaling pathway.

SARS-CoV:5 μM, KCNQ1/KCNE1:4.61 μM (EC50)

Hexachlorophene increases KCNQ1/KCNE1 current amplitude within the concentration range of approximately 0.1 - 10 μM, with an EC₅₀ value of 4.61 μM, and shortens action potential duration [1].
At a concentration of 10 μM, Hexachlorophene can rescue the loss-of-function of LQT mutants caused by impaired gating or reduced PIP₂ binding affinity in CHO cells [1].
Within the concentration range of 0 - 50 μg/mL (with approximately 30 minutes of treatment), Hexachlorophene exhibits antibacterial activity against Micrococcus sp., Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus, with IC₅₀ values of 0.83 μg/mL, 1.5 μg/mL, 1.75 μg/mL, and 1.3 μg/mL, respectively [2].
At a concentration of 20 μM and after 15 hours of treatment, Hexachlorophene inhibits the Wnt/β-catenin signaling pathway in HEK293 and HCT116 cells through Siah-1-mediated β-catenin degradation [3].
Within the concentration range of 0 - 10 μM and after 48 hours of treatment, Hexachlorophene inhibits the growth of HCT116 cells [3].
Hexachlorophene is a competitive inhibitor of the SARS-CoV 3CL protease, with an IC₅₀ value of 5 μM, and forms hydrogen bonds with SARS-CoV 3CL, with an estimated Ki value of 4 μM [4].

One day before mice were exposed to Schistosoma mansoni cercariae (Puerto Rico strain, WRAIR source), their tails were treated with a 1.25% w/v Hexachlorophene solution via tail immersion (5 minutes). This treatment exhibited inhibitory activity against schistosome infection in mice [6].
Hexachlorophene possesses acute and subacute toxicity, with a median lethal dose (LD₅₀) range of 21.8–40.0 mg/kg for intraperitoneal injection and 57.6–87.0 mg/kg for oral administration [5].